Skip to main content

Diabetes

  • ShopRite offers free health-and-wellness offerings

    KEASBEY, N.J. — ShopRite is introducing a variety of health and wellness offerings for its supermarket customers throughout 2017.

    These services include:

    Free Eat Well, Be Happy Weight Management Classes — This six-week class teaches portion control, label reading, better-for-you cooking techniques and lifestyle maintenance.

    Free Diabetes Classes — Runs throughout the year and features one-hour long sessions focusing on several aspects of diabetes. Held in partnership with ShopRite Pharmacy.

  • Dexcom Glucose Monitoring System classified as ‘therapeutic’ by CMS

    SAN DIEGO — The U.S. Department of Health and Human Services Centers for Medicaid and Medicare Services classified Dexcom’s G5 Mobile Continuous Glucose Monitoring system as “therapeutic,” meaning treatment decisions can be made using the device.

    According to Dexcom, it is the only continuous glucose monitoring system that falls under this designation.

  • White paper: Diabetes diagnoses doubles across pediatric population

    NEW YORK  — Private health insurance claim lines with a type 2 diabetes diagnosis more than doubled in the pediatric population (ages 0 to 22 years) from 2011 to 2015, increasing 109%, according to data from FAIR Health, a national, independent, nonprofit organization dedicated to bringing transparency to healthcare costs and health insurance information.

  • Sanofi announces U.S. availability of Soliqua 100/33

    PARIS — Sanofi on Wednesday announced the U.S. availability of its Soliqua 100/33  (insulin glargine 100 units/mL and lixisenatide 33 mcg/mL) injection pen. The drug, approved by the Food and Drug Administration in November, is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 
     

  • FDA clears integration of OneTouch meter with WellDoc's diabetes management platform

    CHESTERBROOK, Pa. — LifeScan, part of the Johnson & Johnson Diabetes Care Companies, earlier this week announced the U.S. Food and Drug Administration has cleared the wireless integration of the OneTouch Verio Flex blood glucose monitoring system with WellDoc's clinically validated diabetes management platform, BlueStar, creating a unique digital health solution for people living with Type 2 diabetes.

  • Lilly, Boehringer Ingelheim launch Lantus follow-on Basaglar

    INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals on Thursday announced the launch and availability of their Basaglar. The drug is a follow-on insulin to U-100 insulin glargine Lantus and is a long-acting insulin with an amino acid sequence identical to that of Lantus. 
     

  • FDA approves Synjardy XR from Lilly, Boehringer Ingelheim

    RIDGEFIELD, Conn. and INDIANAPOLIS — The Food and Drug Administration has approved Eli Lilly & Co.’s and Boehringer Ingelheim’s Synjardy XR (empagliflozin and metformin hydrochloride) extended-release tablets. The drug is indicated to improve blood sugar in adults with Type 2 diabetes when both empagliflozin and metformin can be taken. 
     

  • Lilly rolls out insulin discount program

    INDIANAPOLIS, Ind. —  Eli Lilly & Co. has outlined a new initiative, set to begin Jan. 1, 2017, that will offer access to Lilly insulin at discounted prices to patients via Blink Health’s mobile and web platforms through a partnership with Express Scripts. 
     
X
This ad will auto-close in 10 seconds